- Home
- TXMD vs NEA Comparison
TXMD vs NEA Comparison
Compare TXMD & NEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXMD
- NEA
- Stock Information
- Founded
- TXMD 2008
- NEA 2002
- Country
- TXMD United States
- NEA United States
- Employees
- TXMD N/A
- NEA N/A
- Industry
- TXMD Biotechnology: Pharmaceutical Preparations
- NEA Finance/Investors Services
- Sector
- TXMD Health Care
- NEA Finance
- Exchange
- TXMD Nasdaq
- NEA Nasdaq
- Market Cap
- TXMD 12.8M
- NEA N/A
- IPO Year
- TXMD N/A
- NEA N/A
- Fundamental
- Price
- TXMD $1.13
- NEA $10.98
- Analyst Decision
- TXMD
- NEA
- Analyst Count
- TXMD 0
- NEA 0
- Target Price
- TXMD N/A
- NEA N/A
- AVG Volume (30 Days)
- TXMD 60.3K
- NEA 803.4K
- Earning Date
- TXMD 08-11-2025
- NEA 01-01-0001
- Dividend Yield
- TXMD N/A
- NEA 4.23%
- EPS Growth
- TXMD N/A
- NEA N/A
- EPS
- TXMD N/A
- NEA N/A
- Revenue
- TXMD $1,841,000.00
- NEA N/A
- Revenue This Year
- TXMD $427.09
- NEA N/A
- Revenue Next Year
- TXMD N/A
- NEA N/A
- P/E Ratio
- TXMD N/A
- NEA N/A
- Revenue Growth
- TXMD 53.55
- NEA N/A
- 52 Week Low
- TXMD $0.70
- NEA $9.20
- 52 Week High
- TXMD $2.44
- NEA $11.37
- Technical
- Relative Strength Index (RSI)
- TXMD 44.02
- NEA 61.53
- Support Level
- TXMD $1.07
- NEA $10.79
- Resistance Level
- TXMD $1.21
- NEA $10.97
- Average True Range (ATR)
- TXMD 0.09
- NEA 0.07
- MACD
- TXMD 0.00
- NEA 0.02
- Stochastic Oscillator
- TXMD 54.68
- NEA 97.69
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.